Binnacle Investments Inc Supernus Pharmaceuticals, Inc. Transaction History
Binnacle Investments Inc
- $137 Billion
- Q1 2025
A detailed history of Binnacle Investments Inc transactions in Supernus Pharmaceuticals, Inc. stock. As of the latest transaction made, Binnacle Investments Inc holds 11 shares of SUPN stock, worth $356. This represents 0.0% of its overall portfolio holdings.
Number of Shares
11Holding current value
$356% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding SUPN
# of Institutions
304Shares Held
59.5MCall Options Held
12.1KPut Options Held
6K-
Black Rock Inc. New York, NY10.4MShares$337 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.16MShares$200 Million0.0% of portfolio
-
Armistice Capital, LLC New York, NY4.84MShares$157 Million2.47% of portfolio
-
Dimensional Fund Advisors LP Austin, TX2.9MShares$94.1 Million0.02% of portfolio
-
Macquarie Group LTD Australia, C32.63MShares$85.2 Million0.11% of portfolio
About SUPERNUS PHARMACEUTICALS, INC.
- Ticker SUPN
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 53,495,300
- Market Cap $1.73B
- Description
- Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...